2012
DOI: 10.1517/13543784.2012.719872
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Although studies support the hypothesis that the inactivation of 5-HT(2A) and/or 5-HT(2C) receptors might be of interest to reinforce different facets of the therapeutic activity of SSRIs, this pharmacological strategy remains debatable notably because of the lack of chronic data in relevant animal models. Conversely, emerging evidence suggests that the activation of 5-HT(2B) receptor is required for antidepressant-like activity, opening the way to new therapeutic approaches. However, the potential risks relat… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
33
0
1

Year Published

2013
2013
2018
2018

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 50 publications
(35 citation statements)
references
References 225 publications
1
33
0
1
Order By: Relevance
“…5-HT 1A and 5-HT 2A/2C receptors were investigated in the present study because these receptors play important roles in the antidepressant and anxiolyticlike effects of agents (24,25). We found that the effect of MPEP was blocked by a 5-HT 2A/2C receptor antagonist, ritanserin, but not by a 5-HT 1A receptor antagonist, WAY100635, in the NSF test.…”
Section: Discussionmentioning
confidence: 73%
“…5-HT 1A and 5-HT 2A/2C receptors were investigated in the present study because these receptors play important roles in the antidepressant and anxiolyticlike effects of agents (24,25). We found that the effect of MPEP was blocked by a 5-HT 2A/2C receptor antagonist, ritanserin, but not by a 5-HT 1A receptor antagonist, WAY100635, in the NSF test.…”
Section: Discussionmentioning
confidence: 73%
“…However, it is also important to note that ketanserin also exerts antagonistic effects at other 5-HT 2 receptor subtypes (Bard et al., 1996, Herndon et al., 1992). Given that the 5-HT 2B and 5-HT 2C receptor are both strongly implicated in the regulation of behavioral despair and in stress-evoked responses (Mongeau et al., 2010; Quesseveur et al., 2012, Diaz et al., 2016), pharmacological evidence thus far does not allow a clear delineation of the contribution of distinct 5-HT 2 receptor subtypes to the behavioral effects of chronic stress. Although previous reports do not indicate any major developmental changes in the 5-HT2A/ mice (Weisstaub et al., 2006), we cannot preclude the possibility that differences in studies with pharmacological blockade of the 5-HT 2A receptor and the 5-HT 2A receptor deficient mice may also arise due to adaptations ensuing from constitutive loss of the receptor.…”
Section: Discussionmentioning
confidence: 99%
“…Therefore, serotonin 5-HT 1a partial agonists/ antagonists and 5-HT 2a antagonists have shown effectiveness in improving cognition in depression [8,14,16,77], schizophrenia [15,[78][79][80], Alzheimer's and Parkinson's diseases [81][82][83][84].…”
Section: Discussionmentioning
confidence: 99%
“…It is now accepted that drug action can involve plural targets and that polypharmacology-interacting with multiple targets to address disease in more subtle and effective ways-will be a key pharmacological concept in future. MTDL approach [7][8][9][10] has been applied for development of CNS drugs with improved efficacy compared to their precursors, such as dopamine D 2 /D 3 /5-HT 2A antagonism plus 5-HT 1A partial agonism or dual PDE-4/GSK-3 inhibitors for therapy of schizophrenia [11][12][13], monoamine reuptake inhibition plus 5-HT 2C antagonist properties for tricyclic antidepressants [14][15][16], multi-target AChE/BuChE/MAO-A/MAO-B inhibitors for therapy of neurodegenerative Alzheimer's (AD) and Parkinson's diseases (PD) [7,17,18], and range of CNS drug candidates with additional activity on various targets [19][20][21][22]. The potential clinical advantages of novel classes of multi-target agents are efficacy and speed of action, improved tolerance, and therapeutic range [8][9][10]14].…”
Section: Introductionmentioning
confidence: 99%